Background Plasma based EGFR mutation analysis is emerging as a viable alternative to
tumour tissue genotyping for patients with non-small cell lung carcinoma (NSCLC). The …

Background Lung cancer patients with mutations in the epidermal growth factor receptor
(EGFR) are primary candidates for EGFR-targeted therapy. Reliable analyses of such …

Background: Many studies have evaluated the accuracy of EGFR mutation status in blood
against that in tumor tissues as the reference. We conducted this systematic review and …

Background Testing for epidermal growth factor receptor (EGFR) mutation is an important
process in the therapeutic plan of patients with lung cancer. Recently, MassARRAY, based …

Objectives EGFR mutation is a key factor to predict EGFR-TKI efficacy. However, a
significant number of advanced patients do not have sufficient tumor specimens for …

Background The detection of epidermal growth factor receptor (EGFR) mutations in plasma
or serum has previously been reported to be feasible for non-small-cell lung cancer …

Liquid biopsies have increasingly shown clinical utility. Although next-generation
sequencing has been widely used for the detection of somatic mutations from plasma …

Introduction Testing for the epidermal growth factor receptor (EGFR) gene mutations
requires considerable multidisciplinary experience of clinicians (for appropriate patient …

Molecular testing of EGFR is required to predict the response likelihood to targeted therapy
in non–small cell lung cancer. Analysis of circulating tumor DNA in plasma may complement …

Purpose Circulating tumour DNA (ctDNA) is a promising biomarker for detection of non-
invasive epidermal growth factor receptor (EGFR) mutations in patients with non-small-cell …